Fact sheet: Variopartner SICAV SeBiOpp

Fund information

Fund name
Variopartner SICAV Sectoral Biotech Opportunities I USD
Fund company manager
Vontobel Asset Management S.A.
Fund type
SIB
Fund manager
Mina Marmor
since 31/05/2016
Fund objective
While respecting the principle of risk diversification, the Sub-Fund's assets are primarily invested in shares, equity-like transferable securities, participation certificates etc. issued by companies worldwide which are active in the generics sector. No geographical restrictions apply re. specific countries or regions.
Benchmark
Nasdaq Biotech Index
Investment style
None
Investment method
Shares

Quick stats

1 Year return

26.73 %

1 Year rank in sector

1/29

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 124.2 m

FE Risk score

242

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    85.7%
  • Israel
    4.3%
  • Money Market
    3.6%
  • France
    2.9%
  • Canada
    1.3%
  • Biotechnology/Medical
    87.4%
  • Pharmaceuticals
    9%
  • Money Market
    3.6%
  • US Equities
    85.7%
  • Israeli Equities
    4.3%
  • Money Market
    3.6%
  • French Equities
    2.9%
  • Canadian Equities
    1.3%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund6.09 %20.67 %26.73 %0 %0 %
Sector2.44 %5.7 %6.98 %21.14 %97.17 %
Rank within sector3 / 301 / 301 / 29 / /
Quartile th1 st1 st1 st th th

Calendar performance

YTD-20172016201520142013
Fund47.45 %-22.42 %0 %0 %0 %
Sector15.5 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector1 / 2927 / 29 / / /
Quartile th1 st4 th th th th

Price movement

52 week high10.22
52 week low6.48
Current bid price0
Current offer price0
Current mid price10.1

Holdings by region

  • 85.7% USA
  • 4.3% Israel
  • 3.6% Money Market
  • 2.9% France
  • 1.3% Canada
  • 1.2% Switzerland
  • 1% Sweden

Holdings by sector

  • 87.4% Biotechnology/Medical
  • 9% Pharmaceuticals
  • 3.6% Money Market

Holdings by asset type

  • 85.7% US Equities
  • 4.3% Israeli Equities
  • 3.6% Money Market
  • 2.9% French Equities
  • 1.3% Canadian Equities
  • 1.2% Swiss Equities
  • 1% Swedish Equities

Individual holdings

  • 7.2% REGENERON PHARMACEUTICALS INC
  • 5.9% AMICUS THERAPEUTICS
  • 4.8% ACADIA PHARMACEUTICALS INC
  • 4.7% PORTOLA PHARMACEUTICALS INC
  • 4.5% VERTEX PHARMACEUTICALS INC
  • 4.1% AERIE PHARMACEUTICALS INC
  • 3.8% CELGENE CORP
  • 3.7% ACCELERON PHARMA INC
  • 3.3% GLOBAL BLOOD THERAPEUTICS INC
  • 3.3% LOXO ONCOLOGY INC